M&A Deal Summary |
|
|---|---|
| Date | 2025-02-26 |
| Target | Syros Pharmaceuticals - Tamibarotene clinical and non-clinical assets |
| Sector | Life Science |
| Buyer(s) | Rege Nephro |
| Sellers(s) | Syros Pharmaceuticals |
| Deal Type | Divestiture |
SEARCH BY
Rege Nephro is a biotechnology company focused on developing innovative solutions for kidney diseases, aiming to improve the quality of life for patients. Rege Nephro was founded in 2019 and is based in Kyoto, Japan.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 2011 |
| Sector | Life Science |
Syros Pharmaceuticals is a biopharmaceutical company applying a pioneering approach to discover and develop medicines that control the expression of genes with the aim of treating cancer and other serious diseases.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
